MSU
CDIO icon

Mizuho Securities USA’s Cardio Diagnostics CDIO Stock Holding History

Mizuho Securities USA’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,453
Closed -$3.98M – 231
2022
Q2 		$3.98M Buy
13,453
+1,786
+15% +$532K 0.61% 50
2022
Q1 		$3.43M Buy
+11,667
New +$3.45M 0.49% 74

Other funds holding CDIO

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Mizuho Securities USA's CDIO Position: Q3 2022 in Review

Mizuho Securities USA sold out of Cardio Diagnostics (CDIO) in Q3 2022, closing a stake of 13,453 shares — an estimated $3.98M sold.

Mizuho Securities USA first reported a position in CDIO in Q1 2022 and held it in 2 quarters. The position peaked at $3.98M in Q2 2022. 35 funds tracked by Wall St. Rank hold CDIO as of Q3 2022.

  • Mizuho Securities USA reported no remaining Cardio Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Mizuho Securities USA sold 13,453 Cardio Diagnostics shares in Q3 2022, an estimated $3.98M.
  • Mizuho Securities USA first reported a position in Cardio Diagnostics in Q1 2022 and held it in 2 quarters.
  • Mizuho Securities USA's Cardio Diagnostics position peaked at $3.98M in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q3 2022.

Based on Mizuho Securities USA's 13F filing for Q3 2022, filed 24 Oct 2022.